Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for reducing blood loss during abdominal myomectomy
IRCT20250726066636N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of oxytocin in Fibromyoma (LM) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Blood loss. Started Sep 2025; status: completed.
02
Drugs
oxytocin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20250726066636N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250726066636N1.